- Previous Close
250.07 - Open
252.07 - Bid 247.00 x 900
- Ask 251.13 x 1400
- Day's Range
245.15 - 252.94 - 52 Week Range
192.35 - 281.70 - Volume
2,395,390 - Avg. Volume
2,352,567 - Market Cap (intraday)
180.619B - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
47.19 - EPS (TTM)
5.25 - Earnings Date Jan 28, 2025 - Feb 3, 2025
- Forward Dividend & Yield 1.08 (0.43%)
- Ex-Dividend Date Sep 27, 2024
- 1y Target Est
288.34
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
www.danaher.com61,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DHR
View More
Performance Overview: DHR
Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DHR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DHR
View MoreValuation Measures
Market Cap
180.62B
Enterprise Value
195.52B
Trailing P/E
47.18
Forward P/E
29.41
PEG Ratio (5yr expected)
2.94
Price/Sales (ttm)
7.81
Price/Book (mrq)
3.52
Enterprise Value/Revenue
8.23
Enterprise Value/EBITDA
27.23
Financial Highlights
Profitability and Income Statement
Profit Margin
16.39%
Return on Assets (ttm)
3.86%
Return on Equity (ttm)
7.59%
Revenue (ttm)
23.74B
Net Income Avi to Common (ttm)
3.93B
Diluted EPS (ttm)
5.25
Balance Sheet and Cash Flow
Total Cash (mrq)
2.63B
Total Debt/Equity (mrq)
36.69%
Levered Free Cash Flow (ttm)
5.17B
Research Analysis: DHR
View MoreCompany Insights: DHR
DHR does not have Company Insights
Research Reports: DHR
View MoreDanaher's Bioprocessing Business Is Showing Signs of a Turnaround
In 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
RatingPrice TargetEnd markets strengthening on higher order volume
Danaher is a diversified life sciences and diagnostics company with global operations. Its products and solutions support the biopharma industry in the development and production of therapies. Its Diagnostics segment provides clinical instruments, reagents, and consumables to hospitals, physicians' offices, and reference laboratories. In March 2020, it acquired the GE Biopharma business and renamed it Cytiva. Danaher has continued to make acquisitions, including Aldevron in 2021 and Abcam in 2023. These acquisitions broaden its technology offerings and expand manufacturing capabilities.
RatingPrice TargetOne of the biggest surprises in 2024 has been the spectacular move
One of the biggest surprises in 2024 has been the spectacular move of the Utility (XLU) sector, with a 32.4% leap and a place atop the eleven S&P 500 sectors. We're pretty confident that no one saw that coming. Of course, these aren't your grandfathers' utilities, but rather 'potential' growth stocks where capital gains have taken over for high dividend yields. The conventional electricity industry has soared over 34%, multi-utilities are up 22%, and gas distribution has climbed by 17%. Some of the biggest gainers by market cap this year are NEE (+43%), SO (+37%), CEG (+133%), and VST (243%) in conventional electricity; DUK (+28%), D (+32%), and PEG (+50%) in multi-utilities; and ATO (+26%), NI (+36%), BIPC (+28%), and NFG (+29%) in gas distribution. Coming in second in the sector race, and maybe another surprise, is Financial (XLF), with a 28% gain. The big industry winner has been property & casualty insurance, spiking 38%. P&C is led by PGR (+59%), CB (+35%), and TRV, ALL and ACGL (all up over 40%). Asset managers have also had a great year, rising 33%. Winners here include BX (+34%), BLK (+26%), APO and BLK (both up over 50%), and BAM (+32%). After that comes Communication Services (XLC +27%), Industrials (XLI +23%), Information Technology (XLK +21%), Consumer Staples (XLP +17%), Materials (XLB +16%), and Real Estate and Healthcare (+14%). With broad strength like that, just throw a dart!
Danaher's Bioprocessing Business Is Showing Signs of a Turnaround
In 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
RatingPrice Target